Comparison of graft-versus-host disease-free, relapse-free survival of transplantation using matched sibling donor, matched unrelated donor or unrelated cord blood after myeloablative conditioning for adult patients with hematological malignancies

Abstract

The novel composite endpoint of graft-versus-host disease/relapse-free survival (GRFS) was proposed to evaluate ideal healthy recovery without ongoing morbidity in patients undergoing allogeneic hematopoietic cell transplantation (HCT). We herein analyzed long-term GRFS based on the data of 256 patients with hematological malignancies who underwent allogeneic HCT after myeloablative conditioning. The probabilities of GRFS in the entire cohort were 60.1% at 1 year, and 48.6% at 5 years. Compared with unrelated cord blood, the probability of treatment failure as defined by GRFS at 5 years was similar with matched sibling donor (hazard ratio [HR]: 1.33; p = 0.28), but was significantly higher with matched unrelated donor (HR: 1.96; p = 0.01) in multivariate analysis. Unrelated cord blood achieved the highest proportion of patients who had not experienced any GRFS events at 5 years. These data suggest that long-term GRFS after HCT was similar in matched sibling donor recipients to unrelated cord blood recipients.

Keywords:

• Allogeneic hematopoietic cell transplantation
• graft-versus-host disease/relapse-free survival
• matched sibling donor
• matched unrelated donor
• unrelated cord blood

Acknowledgements

The authors would like to thank all of the physicians and staff at the hospital, the Japan Marrow Donor Program, and the Japan Cord Blood Bank Network for their help in this study.

Potential conflict of interests

Disclosure forms provided by the authors are available with the full text of this article at http://dx.doi.org/10.3109/10428194.2015.1122784

This work was supported in part by The Kobayashi Foundation.